- Adcirca® FAQ
- BiPAP / CPAP
- Calcium Channel Blockers
- Endothelin Receptor Antagonists
- Epoprostenol for Injection
- Epoprostenol sodium
- Inhaled Treprostinil
- Nitric Oxide
- Oral Remodulin®
- Orral treprostinil
- Other Drugs and Treatments
- Phosphodiesterase type-5 Inhibitor
- Sildenafil Citrate
- Sitaxsentan Sodium
- Tracleer® FAQ
- Under FDA Review
Remodulin®, (also known as UT-15) is a synthetic, stable form of prostacyclin for either subcutaneous infusion delivery or intravenous delivery. Additionally, there is an inhaled version of Remodulin known as Tyvaso®, which was approved by the FDA in July 2009.
Remodulin is a potent vasodilator that relaxes the blood vessels in the lungs and slows the process of scarring and cell growth within the lung’s blood vessels, which prevents further narrowing. It also assists in increasing cardiac output and oxygen saturation. It improves exercise tolerance and prolongs survival in patients with PAH. It is a second generation to Flolan®, although produced by a different drug company.
Remodulin has a much longer half-life in the human body than Flolan so it reduces the danger if infusion is interrupted. Additionally Remodulin is stable at room temperature for up to five years, unlike Flolan. The drug's dilation action lasts from 4-6 hours versus the short 2-3 minute action of Flolan.
Fda approval date
Remodulin can be administered in two ways. For under the skin delivery, called subcutaneous infusion, Remodulin is infused with a pager-sized MiniMed microinfusion device (see picture 1-A).
Subcutaneous Remodulin lowers the risk of infection and related hospitalizations associated with the Flolan central line catheter.
For intravenous delivery, Remodulin is delivered through a central line catheter, much like Flolan (see picture 2-A)
Remodulin does not require mixing; the fluid comes ready-to-use in glass vials. No refrigeration is needed. A small syringe is used to withdraw solution and the syringe itself becomes the cassette placed into the pump. Every three days, a new site on the belly is begun, using a spring-loaded device to insert a very thin plastic cannula approximately 1/2 inch into the belly.
The Mini-Med Subcutaneous
The AutoCadd Legacy Pump
The chief drawback to Remodulin is site pain, which can be quite severe. Often a pain medication must be prescribed for Remodulin patients. However, for those patients unable to tolerate the site pain, Remodulin can now be delivered intravenously.
Remodulin has the same side effects as Flolan, but often not as severe. Side effects can include jaw pain, headache, flushing, nausea, diarrhea, and vomiting.
The yearly cost of Remodulin is upwards of $100,000 per year, dependent on the patient and dosage. Many insurance companies consider it an ongoing treatment rather than a prescription, so it's classified differently where co-pays are concerned.
Full Prescribing Information
For Additional Information Visit:
- United Therapeutics Website
- Clinical Trial Information for Inhaled Remodulin®
- Slide Presentation to FDA: NDA 21-272Remodulin®™ (treprostinil sodium)
- Safety, Efficacy and Treatment Satisfaction Switching From Flolan to Remodulin
- Remodulin Therapy Assistance Program
Page Reviewed/Edited: November 2010
In The News
- June 17, 2015
- Insmed: INS1009, inhaled treprostinil prodrug for PAH treatment
- January 10, 2015
- United Therapeutics and DEKA Sign Agreement for New PAH Remodulin Delivery System
- October 18, 2014
- Pulmonary Arterial Hypertension: A Better Understanding of the Three New Drug Therapies
- September 5, 2014
- United Therapeutics Blocks Generic PAH Drug For Remodulin in Patent Case
- July 9, 2014
- Pulmonary Hypertension in Infants: Subcutaneous Treprostinil?
- December 29, 2013
- 5th World Congress of PAH - get papers for free!
- March 26, 2013
- FDA rejects new United Therapeutics drug
- February 20, 2013
- United Therapeutics retransmitted drug application for oral remodulin
- January 27, 2013
- Oral Treprostinil Improves Exercise Capacity in Pulmonary Arterial Hypertension
- August 25, 2012
- Effectiveness and Safety of Inhaled Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Children.
- April 9, 2012
- Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension.
- April 9, 2012
- Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors
- March 15, 2012
- United Therapeutics sues Sandoz over hypertension drug
- February 21, 2012
- Oral Treprostinil New Drug Application Accepted by FDA for Review
- February 9, 2012
- Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension.
- February 7, 2012
- United Therapeutics to Fight Sandoz Bid to Sell Generic Version of PAH
- February 6, 2012
- Inhaled treprostinil: a therapeutic review
- November 16, 2011
- CHEST: Oral Prostanoid Shows Promise in PAH
- August 24, 2011
- United Therapeutics oral lung drug fails trial, shares slide
- January 23, 2011
- Differential Response to Intravenous Prostacyclin Analog Therapy in Patients with PAH
- November 5, 2010
- BioTech CEOs offer cautionary tales
- September 23, 2010
- Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations.
- April 27, 2010
- Standard PAH therapy improves long term survival in CTEPH patients.
- December 28, 2009
- PAH Drug Outperforms Expectations